Lupin has received approval for incorporation of a Wholly Owned Subsidiary (WOS) in the name and style ‘LUPINLIFE Consumer Healthcare’ or any other appropriate name, as may be approved by the Ministry of Corporate Affairs. The proposed New WOS will be incorporated with an objective to carry out the business of trading and manufacturing of various types of consumer healthcare products predominantly over the counter drugs and products.
The company has also received approval for transfer of the Over-the-Counter (OTC) Consumer Healthcare Business of the Company, on a slump sale basis, to a wholly owned subsidiary that is proposed to be incorporated.
The Board of Directors of the Company, at its meeting held on February 11, 2025, inter alia, considered and unanimously approved the same.
Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1847.30 |
| Dr. Reddys Lab | 1293.25 |
| Cipla | 1347.70 |
| Zydus Lifesciences | 938.90 |
| Lupin | 2377.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: